West Pharmaceutical Services has introduced a new 0.5 mL plunger within its NovaPure® portfolio, extending its range of ready-to-use elastomer components for ISO glass syringes. The development specifically targets ophthalmic drug delivery, a segment facing increasing technical and regulatory pressure.
Driven by ageing populations and the rising prevalence of retinal diseases, ophthalmic injectables are growing rapidly. However, these applications require precise delivery at microvolumes, where even minor variations in container closure performance can impact dosing accuracy and product quality.
The newly launched plunger has been designed to address these constraints. It features a reduced risk of free silicone oil, low particulate and endotoxin levels, and consistent functional performance. According to the company, it also optimises break-loose and glide forces while limiting drug–container interactions — parameters that are particularly critical in ophthalmic formulations.
Beyond performance, the launch reflects evolving regulatory expectations. With increasing focus on contamination control strategies under EU GMP Annex 1, packaging components are expected to demonstrate a high level of consistency and cleanliness, especially in sterile and sensitive applications.
This extension of the NovaPure® platform illustrates a broader shift across the injectable landscape: packaging is becoming an integral part of drug development strategies, particularly in specialised areas such as ophthalmology, where precision and reliability are essential.